Treatment of HCV infection by targeting microRNA.
暂无分享,去创建一个
S. Kauppinen | S. Zeuzem | H. Janssen | A. Levin | M. Rodríguez-Torres | A. Patick | R. Persson | H. Reesink | K. Patel | E. Lawitz | A. J. van der Meer | Alice Chen | Yi Zhou | B. King | M. Hodges | M. Rodríguez-Torres
[1] M. Manns,et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. , 2012, JAMA.
[2] K. Chayama,et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders , 2012, Hepatology.
[3] Anna Persson,et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. , 2012, The New England journal of medicine.
[4] S. Lemon,et al. Stabilization of hepatitis C virus RNA by an Ago2–miR-122 complex , 2012, Proceedings of the National Academy of Sciences.
[5] E. Olson,et al. Therapeutic Inhibition of miR-208a Improves Cardiac Function and Survival During Heart Failure , 2011, Circulation.
[6] S. Kauppinen,et al. Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice , 2011, EMBO molecular medicine.
[7] Michael Adler,et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. , 2011, The New England journal of medicine.
[8] P. Belperio,et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[9] Sprint Investigators,et al. Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .
[10] J. Bukh,et al. MicroRNA-122 antagonism against hepatitis C virus genotypes 1–6 and reduced efficacy by host RNA insertion or mutations in the HCV 5′ UTR , 2011, Proceedings of the National Academy of Sciences.
[11] P. Sarnow,et al. Masking the 5′ terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex , 2011, Proceedings of the National Academy of Sciences.
[12] M. Manns,et al. Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.
[13] Jacques Fellay,et al. IL28B genotype is associated with differential expression of intrahepatic interferon‐stimulated genes in patients with chronic hepatitis C , 2010, Hepatology.
[14] William M. Lee,et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C , 2010, Hepatology.
[15] Robert A. Weinberg,et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model , 2010, Nature Biotechnology.
[16] S. Kauppinen,et al. Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection , 2010, Science.
[17] S. Thorgeirsson,et al. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties , 2009, Oncogene.
[18] Hsien-Da Huang,et al. MicroRNA‐122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma , 2009, Hepatology.
[19] W. Filipowicz,et al. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy , 2009, Nature Medicine.
[20] Michael Niepmann,et al. microRNA-122 stimulates translation of hepatitis C virus RNA , 2008, The EMBO journal.
[21] S. Kauppinen,et al. LNA-mediated microRNA silencing in non-human primates , 2008, Nature.
[22] Krista A. Zanetti,et al. Identification of metastasis‐related microRNAs in hepatocellular carcinoma , 2008, Hepatology.
[23] A. Silahtaroglu,et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver , 2007, Nucleic acids research.
[24] Peter Schirmacher,et al. MicroRNA gene expression profile of hepatitis C virus–associated hepatocellular carcinoma , 2007, Hepatology.
[25] An Overview of the Clinical Safety Experience of First- and Second-Generation Antisense Oligonucleotides , 2007 .
[26] T. Okanoue,et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues , 2006, Oncogene.
[27] Mark Graham,et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. , 2006, Cell metabolism.
[28] N. Rajewsky,et al. Silencing of microRNAs in vivo with ‘antagomirs’ , 2005, Nature.
[29] P. Sarnow,et al. Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA , 2005, Science.
[30] P. Terasaki,et al. Liver transplantation in the United States. , 2005, Clinical transplants.
[31] V. Ambros. The functions of animal microRNAs , 2004, Nature.
[32] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.